Abstract |
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE.
|
Authors | Eleanor Murray, Martin Perry |
Journal | Clinical rheumatology
(Clin Rheumatol)
Vol. 29
Issue 7
Pg. 707-16
(Jul 2010)
ISSN: 1434-9949 [Electronic] Germany |
PMID | 20155295
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Rituximab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, pharmacology, therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- B-Lymphocytes
(cytology, drug effects, immunology)
- Down-Regulation
(drug effects)
- Humans
- Lupus Erythematosus, Systemic
(drug therapy)
- Off-Label Use
- Rituximab
|